Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy: A multicenter retrospective study
Shingo Hatakeyama(Hirosaki University), Chikara Οhyama(Hirosaki University), Eiki Tsushima(Hirosaki University), Tomonori Habuchi(Akita University), Akihiro Ito(Tohoku University), Sadafumi Kawamura(Miyagi Prefectural Hospital Organization), Kazuyuki Numakura(Akita University), Sei Naito(Yamagata University), Norihiko Tsuchiya(Yamagata University), Renpei Kato(Iwate Medical University), Wataru Obara(Iwate Medical University), Takahiro Kojima(Aichi Cancer Center), Hiroyuki Nishiyama(University of Tsukuba), Yoshihide Kawasaki(Tohoku University), Shuya Kandori(University of Tsukuba), Yoshiyuki Kojima(Fukushima Medical University), Tomoyuki Koguchi(Fukushima Medical University)
Cited by 14
Related Papers
A cross-population atlas of genetic associations for 220 human phenotypes
|Nature Genetics|2021|2.4k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
|Nature|2021|603